54 results about "Heart disorder" patented technology

The invention concerns methods for treating cardiac remodeling in a subject who has undergone myocardial injury, said method comprising the administration of natriuretic peptide to said subject. Preferably the natriuretic peptide is brain natriuretic peptide. The invention also concerns methods for treating structural heart disorders arising from myocardial injury, said method comprising the administration of a natriuretic peptide to a patient in need thereof.

The present invention is directed to a method for diagnosing silent and / or symptomatic cardiac diseases in human patients, based on extracting and analyzing hidden factors or a combination of hidden and known factors of ECG signals. The diagnosis method employs rest-ECG signals of a group of diagnosed patients, the group consisting of patients a-priori diagnosed as sick patients and of patients a-priori diagnosed as healthy patients by trusted procedures. Artificial neural networks are then iteratively trained to accurately classify the cardiac disease by processing the corresponding raw input signals of the diagnosed patients. The weights and biases data representing the trained neural networks are saved. Unknown, new patients are diagnosed as sick or healthy patients by processing their corresponding raw ECG signals by the trained neural networks.

The present invention relates generally to a diagnostic device including a prognostic assay for parameters which are indicative of a condition or event associated with the systemic vasculature. More particularly, the present invention provides an assay to detect parameters associated with a vascular disease including cardiovascular, stroke, pulmonary, renovascular, cerebrovascular, thrombotic or generalized arterial or venous condition or event including acute coronary syndrome such as but not limited to acute myocardial infarction, heart failure, atheromoma or a thrombotic condition. The identification of these parameters or more particularly a pattern of parameters enables the diagnosis of a condition or event or the determination of the risk of development of a condition or event associated to the systemic vasculature. Still more particularly, the present invention is directed to a diagnostic device comprising a set of members wherein one or more of said members has or have specific or generic binding partners in a biological sample from an animal including human subject wherein the pattern of binding of the members to the binding partners is indicative, predictive or otherwise associated with a likelihood of a condition or event within the systemic vasculature. The absence of detection of specific or generic binding partners is also of indicative or predictive value. This is particularly important in cases where patients are unable to communicate advice to a physician on their own condition, such as during surgery or for patients in a coma. It is also useful in determining the risk of a vascular disease including cardiovascular, stroke, pulmonary, renovascular, cerebrovascular, thrombotic or generalized arterial or venous conditions or events in a healthy subject or a subject entering into an exposure to risk such as surgery or chemotherapy. The present invention is useful inter alia for the identification and / or quantitation of biochemical markers of conditions or events in the systemic vasculature such as heart disease, heart disorders, infections of the heart, stroke and thrombosis as well as the determination of a risk of development of these conditions including the absence of disorders or absence of risk of the development of a disorder. The assessment of such conditions may be made in a clinical setting, as part of triage, as part of a routine testing protocol and / or as a laboratory procedure.

The invention provides a cardiovascular disease early warning system based on the deep fusion of multiple physiological signals, which relates to the technical field of wearable health medical monitoring. The system includes a wearing device, a multi-physiological signal acquisition device, a transmission device, an intelligent terminal device and a cloud server. The multi-physiological signal acquisition device and the transmission device are arranged on the wearing device. The multi-physiological signal collecting device collects the physiological signal of the detected person and transmitsthe collected physiological signal to the intelligent terminal equipment through the transmitting device. The multi-physiological signal collecting device collects the physiological signal of the detected person and transmits the collected physiological signal to the intelligent terminal equipment. The intelligent terminal device has built-in program for judging whether the detected person is at risk of cardiovascular disease and transmitting the processed physiological signals to the cloud server. The cloud server has a built-in program for classifying and diagnosing diseases of multiple physiological signals of the wearer and feeding back the diseases to the intelligent terminal. The cardiovascular disease early warning system based on the deep fusion of multiple physiological signals provided by the invention provides more accurate reference for the evaluation of cardiac function and the diagnosis of cardiac disease.

A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure.

Disclosed are compositions and methods for preventing, treating, or reducing symptoms associated with a myocardial or related disorder such as an infarction. In one embodiment, the method includes administering a therapeutically effective amount of a nucleic acid encoding at least one morphogen; or an effective fragment thereof. Preferred morphogens include the human Sonic Hedghog (Shh), human Desert Hedgehog (Dhh), and human Indian Hedgehog (Ihh) proteins. The methods can be used alone or in combination with other methods involving administration of an angiogenic protein, hematopoietic protein, or endothelial precursor cells (EPCs).

The invention relates to a non-contact heartbeat and breathing disorder monitoring system and a monitoring method. The system and the method are applied to dynamic health monitoring, and are especially suitable for personal daily home monitoring of patients with respiratory and cardiac diseases. The system and the method comprise the following operations: emitting and receiving radar signals via aradar signal module, monitoring the received radar signals in real time and recording breathing and / or heartbeat status information of a monitored object; modulating and amplifying the received radarsignals via an information processing module; conducting data analysis and judgement on the processed signals via a data analysis module; and transmitting processed and analyzed data to a server viaa communication module. With the application of the product (the system and the method), physiological data of human breathing and heartbeat can be periodically and continuously monitored and acquiredin a hidden mode for a long time, and physiological and psychological discomforts caused by wearable equipment can be avoided.

Screening apparently healthy individuals using sensitive techniques for identifying early vascular and cardiac disease provides the opportunity for effective intervention to prevent or delay the occurrence of cardiovascular events which represent the most common cause of morbidity and mortality in our society. Preliminary studies in the have revealed an incidence of over 50% of early disease in need of therapy. The apparent ineffectiveness of the health care system to uncover this early disease emphasizes the need for a more aggressive community approach to screen for early disease and to initiate therapy that should reduce health care costs and improve quality and duration of life.

Pharmaceutically acceptable metal salts of compounds of formula (I): in which R1 is selected from the group consisting of (C1-C6)alkoxy(C1-C6)alkyl which may be substituted with (C1-C6)alkoxy, phenyl-(C1-C6)-alkyl and / or phenyloxy-(C1-C6)-alkyl group in which any phenyl group may be substituted with (C1-C6)alkyl, (C1-C6)alkoxy or halogen, and naphtyl-(C1-C6)-alkyl; R2 and R3 are each independently hydrogen or halogen; R4 is a biolabile ester forming group; and in which the salt is selected from the lithium salt and salts of bivalent metal ions such as magnesium, calcium and zinc. Also described are a method for the preparation of the above salts; pharmaceutical compositions comprising the above salts; methods of using the above salts to treat heart disorders or hypertension, to improve gastrointestinal blood flow, or to treat or inhibit cardiac damage induced by adriamycin and comparable anti-cancer drugs; and crystalline S-α-methylbenzylamine salts of the compounds of formula (I) that are useful as intermediates in production of the above salts.

The invention discloses a portable sleep apnea syndrome monitoring method and device and relates to the field of household medical equipment. The inconvenient use and high cost problems of the existing method and equipment are solved. The device comprises an electrocardio and respiration signal detector attached to the body of a user and a sleep apnea syndrome monitoring software based on intelligent terminal equipment, wherein the electrocardio and respiration signal detector comprises an electrocardio lead wire, an electrocardio signal detecting module, an impedance type respiration detecting module, an analog / digital conversion circuit, a processor and a wireless transmission module; an electrocardio detecting electrode and the lead wire are shared by an impedance type respiration detecting circuit and an electrocardio signal detecting circuit; the sleep apnea syndrome monitoring software on the intelligent terminal equipment realizes processing, storage, playback and display on electrocardio and respiration signals and real-time detection and alarm on sleep apnea and heart disease sudden events. Data transmission is carried out between the electrocardio and respiration signal detector and the intelligent terminal equipment.

New methods and devices for treating heart failure and other cardiac disease conditions. Devices include a cardiac jacket adapted to fit generally around at least a portion of the heart. The jacket in some embodiments includes an electroactive polymer to squeeze the exterior of the heart to assist contraction of one or more pumping chambers, preferably the left ventricle. The jacket may also include stem cells on an inner surface of the jacket. The stem cells differentiate into cardiac tissue and help treatment of heart failure. Some embodiments also involve delivering an electric field or an electric current to electrically conductive material in the jacket to establish an electromagnetic field at the surface of the heart effective to promote growth and differentiation of stem cells into cardiac tissue.

The invention belongs to the technical field of biological detection, and particularly relates to a lipoprotein (a) detection kit. The lipoprotein (a) detection kit provided by the invention is mainlycomposed of an antibody elisa plate, a biotin antibody coated plate, horse radish peroxidase-streptavidin, lipoprotein (a) series standard substances, a diluent, a cleaning solution, a substrate solution, a developing solution and a stop solution. The lipoprotein (a) detection kit provided by the invention has the advantages of simple operation, high sensitivity and strong anti-interference capability, can effectively reduce the interference of other substances in serum, especially the interference effect of an anti-RF factor on a detection result, and greatly improves the accuracy and stability of the detection result. Meanwhile, the kit can also reduce the phenomenon of inaccurate detection results caused by the difference of the copy number of apolipoprotein (a) molecules KringleIV-2 in lipoprotein (a), and is more beneficial to early diagnosis and prognosis treatment of patients with arteriosclerosis and heart diseases.

An oxygen-releasing biomaterial, articles and methods, and more particularly an oxygen-releasing biomaterial with sustained oxygen-releasing properties of four to five weeks, which is suitable for tissue engineering scaffolds, is disclosed. The biomaterial contains a hydrogel with a plurality of microparticles suspended in the hydrogel. The microparticles contain an oxygen carrier that is encapsulated in a biocompatible hydrophobic material, where the release of oxygen from the oxygen carrier is sustained over a four to five week period. The biomaterial has application in tissue engineering, osteogenesis, burn and wound treatment, and treatment of cardiac conditions, and has further antimicrobial properties.

The invention discloses a hear detection and treatment system. The heart detection and treatment system comprises a waistcoat and an outer shell. A power module is fixedly arranged on the waistcoat, a supporting plate is arranged inside the outer shell, and a controller, a high-voltage charger and a heart rate sensor are arranged on one side of the supporting plate. The high-voltage charger and the heart rate sensor are electrically connected with the controller, a pressing motor and heart defibrillation electrodes are arranged on the other side of the supporting plate, the high-voltage charger is electrically connected with the hear defibrillation electrodes, and a pressing head is fixedly arranged on the pressing motor and covered with a rear cover. Fabric electrodes are fixed to the rear cover and electrically connected with the heart rate sensor. Parameter signals about body conditions are transmitted to the controller through the heart rate sensor, the controller compares signal parameters with preset parameters, then auxiliary pressing or hear defibrillation is selectively started, in this way, the symptom of a wearer suffering a sudden heart attack can be relieved, a valuable opportunity can be provided for follow-up treatment, and then the sudden death probability is lowered.

The invention discloses an intelligent ward-type ambulance for ECMO (extracorporeal membrane oxygenation) emergency treatment. The intelligent ward-type ambulance comprises an ambulance body and a compartment, wherein the ambulance body is fixed to the bottom of the compartment and used for providing power and electric power for the compartment. The intelligent ward-type ambulance is characterizedin that emergency treatment equipment for on-site emergency treatment of critical patients is mounted inside the compartment and combined with a vehicular ECMO technology to finish the emergency treatment process of the critical patients. The emergency treatment equipment is arranged inside the ambulance body and comprises a cardio-pulmonary resuscitator, an electrocardiogram device, a respirator, an infusion and injection pump and a defibrillator, pulse current acts on a heart to implement electric-shock treatment and eliminate heart disorder, so that a heart restores sinus rhythm, the emergency treatment equipment is used in the emergency treatment process of the patients, an aspirator is used for adsorbing foreign matters in the surgical process, smoothness of the emergency treatment process is facilitated, so that the emergency treatment equipment can be combined with the vehicular ECMO technology in the emergency treatment process, the life of the critical patients is timely supported and rescued, and the use range of the ambulance is widened.

Methods and apparatuses, including devices and systems, for remote and detection and / or diagnosis of acute myocardial infarction (AMI). In particular, described herein are handheld devices having an electrode configuration capable of recording three orthogonal ECG lead signals in an orientation-specific manner, and transmitting these signals to a processor. The processor may be remote or local, and it may automatically or semi-automatically detect AMI, atrial fibrillation or other heart disorders based on the analyses of the deviation of the recorded 3 cardiac signals with respect to previously stored baseline recordings.

The invention discloses a heart and vital sign monitoring and analyzing system. The system comprises an information acquisition end, a mobile communication end and a remote analysis terminal which are in wireless connection sequentially, wherein the information acquisition end comprises an electrocardiogram information acquisition unit, a vital sign information acquisition unit, a micro-processor and a wireless output module and is used for acquiring electrocardiogram data and vital sign data of a patient in real time and uploading the electrocardiogram data and the vital sign data to the mobile communication end; the mobile communication end is used for processing and storing the received data and uploading the data to the remote analysis terminal; the remote analysis terminal is used for recognizing and analyzing the received data, giving out a detection report or an instructive suggestion and returning a result to the mobile communication end. With the adoption of the heart and vital sign monitoring and analyzing system, activity changes of the heart of the patient can be learned about in different environments in different time according to the electrocardiogram signals and the vital sign information acquired constantly in 24 hours, sudden cardiovascular and cerebrovascular diseases are prevented, and time is earned for early detection and treatment of heart diseases. The system is small and ingenious in structure and convenient to carry and popularize.

The invention discloses blueberry beer with a healthcare function. The blueberry beer mainly comprises barley wort and hops, the raw barley wort concentration before fermentation is 8-14 BX, during blending before fermentation, according to the mass of required products, 20-40 parts of blueberry peel pulp, 20-40 parts of blueberry bee milk honey, 20-50 parts of blueberry seed powder and 10-40 parts of blueberry juice are added and are cultured and fermented together; after fermentation, according to the mass of required products, 1-4 parts of blueberry peel pulp, 1-10 parts of blueberry seed powder, 0.0001-0.004 part of blueberry essence, 1-5 parts of blueberry bee milk honey and 1-5 parts of blueberry juice are blended and added according to mass ratio; the beer comprises more anthocyanin and Vitamine E, so that the beer can have functions of vessel softening, heart disease preventing, senescence delaying, memory improving, and eyesight degrading preventing when being taken moderately in a long term.

The present invention discloses a method and a device for identifying electrocardiogram image feature points, and relates to the technical field of portable medical devices. The method comprises the steps of: obtaining original signals of electrocardiogram images; performing filtering processing for the original signals to obtain signals after filtering; based on the filtered signals, determininga feature point R; and determining other feature points based on the feature point R. The method and the device for identifying electrocardiogram image feature points mainly solve the problem that theQRS feature wave group diagnosis is difficult, are mainly used for a current portable wearable device, and a good diagnosis effect on various types of heart disorder.

Method for treating cardiac diseases using BET inhibitors including JQ1 are provided. Methods for treating cardiac hypertrophy, method for treating heart failure not arising from inflammation, methods for treating myocardial infarction, methods for cardioprotection and methods for inhibiting restenosis are described herein. The methods involve the use of effective amounts of BET inhibitors such as JQ1.

The invention provides a heart sound analysis system based on a probabilistic neural network model. The system consists of a heart sound acquisition processing module and a heart sound intelligent analysis module, a hardware part comprises a heart sound acquisition circuit unit, and a software part comprises a heart sound processing unit, an automatic heart sound diagnosis unit and a data displayunit. The system can realize the automatic diagnosis of common heart diseases by collecting, processing and intelligently analyzing heart sound signals, provide people with health information and health advice, and can be used as hospital auxiliary diagnostic equipment.

A method and device for quantitative analysis of pathological features of electrocardiographic data, relating to a method and device for quantitatively extracting multiple pathological features of a dynamic cardiac electrical activity system and an abnormal analysis method and device for cardiac electrical signals, belonging to the field of heart disease data feature mining and used to solve The problem of digging out more and richer dynamic pathological features in the electrical activity of the cardiac nonlinear system, the key point is to have the ability to extract the quantitative indicators of the cardiac dynamic pathological features inherent in the dynamic data of the nonlinear system of cardiac electrical activity by means of heterogeneity analysis Step, the heterogeneity analysis refers to the inhomogeneity and complexity analysis of the dynamic data of the nonlinear system of cardiac electrical activity in the process of spatial distribution and time deduction, and the effect is: the obtained information can present The dynamic pathological characteristics of the nonlinear system of cardiac electrical activity.

The invention provides an application of CMDL-1, a kit for diagnosis of the heart disease and a drug for treating the heart disease, and relates to the technical field of biomedical engineering. The cDNA sequence of long-chain non-coding RNA CMDL-1 related with the heart disease is represented as SEQ ID NO.1. By means of the experiment, it is discovered that expression of CMDL-1 in myocardial cells stimulated by adriamycin is obviously down-regulated, and the purpose of diagnosis of the heart disease can be achieved by specific detection for CMDL-1. Meanwhile, by means of overexpression of CMDL-1, chondriokinesis of the myocardial cells induced by adriamycin can be effectively inhibited, and furthermore, apoptosis of the myocardial cells due to adriamycin induction is effectively reduced.CMDL-1 is expected to provide significant biological indicators for clinical diagnosis and treatment of the heart disease, and new effect targets and new ideas are provided for heart disease resistantdesign.